HC Wainwright Begins Coverage on Savara (NASDAQ:SVRA)

Equities research analysts at HC Wainwright initiated coverage on shares of Savara (NASDAQ:SVRA – Get Free Report) in a note issued to investors on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. HC Wainwright‘s price objective would indicate a potential upside of 115.52% from the company’s current price.

A number of other research analysts have also issued reports on SVRA. Citigroup reiterated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research report on Wednesday, October 7th. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. JPMorgan Chase & Co. assumed coverage on Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.29.

Get Our Latest Stock Report on SVRA

Savara Price Performance

Shares of NASDAQ:SVRA opened at $4.64 on Thursday. Savara has a one year low of $4.13 and a one year high of $7.01. The company has a 50-day simple moving average of $4.93 and a 200-day simple moving average of $5.34. The company has a quick ratio of 10.13, a current ratio of 8.55 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. As a group, equities research analysts forecast that Savara will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of large investors have recently bought and sold shares of SVRA. Profund Advisors LLC boosted its position in shares of Savara by 7.3% in the third quarter. Profund Advisors LLC now owns 49,741 shares of the company’s stock worth $257,000 after acquiring an additional 3,370 shares during the last quarter. Sterling Capital Management LLC grew its holdings in Savara by 842.8% in the third quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock valued at $26,000 after purchasing an additional 4,526 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Savara by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company’s stock worth $190,000 after purchasing an additional 4,874 shares during the last quarter. Arizona State Retirement System increased its position in Savara by 34.0% during the second quarter. Arizona State Retirement System now owns 25,445 shares of the company’s stock worth $157,000 after purchasing an additional 6,456 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Savara during the first quarter worth approximately $57,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

(Get Free Report)

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.

Read More

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.